Activated recombinant factor VIIa should not be used in patients with refractory variceal bleeding: it is mostly ineffective, is expensive, and may rarely cause serious adverse events [PDF]
, 2014 Activated Recombinant Factor VIIa Does Not Improve Mortality in Variceal Bleeding. Bendtsen F, D’Amico G, Rusch E, de Franchis R, Anderson PK, Lebrec D, et al. Effect of recombinant Factor VIIa on outcome of acute variceal bleeding: An individual patient
Chalasani, Naga, Sozio, Margaret S.
core +1 more source
Use of recombinant factor VIIa in the treatment of massive retroperitoneal bleeding due to severe necrotizing pancreatitis [PDF]
, 2009 Background. Recently, a growing number of case reports and case series have suggested that the use of recombinant activated factor VII (rFVIIa) may be effective in treatment of patients with non-hemophilic acquired coagulopathy not responding to ...
Lačković Vesna +6 more
core +1 more source
Trombastenia de Glanzmann. Histerectomia vaginal de urgência tratada com factor VIIa recombinante.
Acta Médica Portuguesa, 2004 In the present article, regarding a clinical case of Thrombasthenia of Glanzmann with severe anaemia by menometrorrhagia, the authors propose the vaginal hysterectomy and the administration of the recombinant factor VIIa on the immediate pre and ...
João S Mairos +10 more
doaj +1 more source
Stroke intensive care: voice a view
Анналы клинической и экспериментальной неврологии, 2007 Modern methods of acute stroke treatment are analyzed: traditional and mechanical thrombolysis, intraventricular thrombolysis, recombinant activated factor VIIa for acute intracerebral hemorrhage, hemicraniectomy.
M. A. Piradov
doaj +1 more source
Acquired Hemophilia A: A Permanent Challenge for All Physicians
Medicines, 2022 Acquired hemophilia A (AHA) is a rare disease with a prevalence in Europe of 1.5 per million. This diagnosis is significantly delayed in about one-third of all cases, leading to deferred treatment.
Knut M. Nowak +3 more
doaj +1 more source
Acquired factor VII inhibitor associated with primary central nervous system Lymphoma: A case report
eJHaem, 2022 Paraneoplastic coagulopathies are uncommon in patients with lymphoma. We report the first case of an acquired coagulopathy in a patient with isolated primary central nervous system lymphoma (PCNSL) demonstrating large‐cell histology.
Vanshika Goyal +4 more
doaj +1 more source
The use of recombinant factor VIIa in a pediatric septic shock patient with disseminated intravascular coagulation [PDF]
Einstein (São Paulo), 2008 This is a report on a pediatric patient with septic shock and disseminated intravascular coagulation, who developed life-threatening bleeding which was successfully treated with recombinant factor VIIa.
Ronaldo Arkader +2 more
doaj
Analysis of the potential of cancer cell lines to release tissue factor-containing microvesicles: correlation with tissue factor and PAR2 expression [PDF]
, 2016 BackgroundDespite the association of cancer-derived circulating tissue factor (TF)-containing microvesicles and hypercoagulable state, correlations with the incidence of thrombosis remain unclear.MethodsIn this study the upregulation of TF release upon ...
A Bharthuar +57 more
core +2 more sources
Hematology Reports, 2018 A 52 year-old male presented with neck pain after undergoing thyroidectomy for a goiter three weeks prior which was complicated by a neck hematoma requiring evacuation.
Anthony L. Nguyen +3 more
doaj +1 more source
FEBS Open Bio, EarlyView.Activation of the mitochondrial protein OXR1 increases pSyn129 αSynuclein aggregation by lowering ATP levels and altering mitochondrial membrane potential, particularly in response to MSA‐derived fibrils. In contrast, ablation of the ER protein EMC4 enhances autophagic flux and lysosomal clearance, broadly reducing α‐synuclein aggregates.
Sandesh Neupane +11 more
wiley +1 more source